Antiplatelets In The Wilderness After Mixed Results From DAPT Study
This article was originally published in The Pink Sheet Daily
FDA seems more concerned about mortality than most academics following trial of dual antiplatelet therapy after stenting; AstraZeneca sees potential opening for Brilinta.
You may also be interested in...
In patients implanted with drug-eluting stents, dual antiplatelet drug therapy beyond one year significantly reduces the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events compared to aspirin alone, but also increase the risk of bleeding, the Dual Antiplatelet Therapy Trial show.
Study aims to identify optimum duration of anti-clotting drugs for stent patients; enrollment targeted at 20,000 patients.
Overall study group, however, did not show reduction in risk in combined rate of death, heart attack or stroke from combination therapy of Plavix and low-dose aspirin.